Table 5.
Changes in demographic, prognostic, and laboratory results in patients with severe sepsis with or without continuous hemofiltration.
| CRRT (n = 23) Median (Min–Max) |
CRRT+TPE (n = 24) Median (Min–Max) |
Without CRRT or TPE (n = 116) Median (Min–Max) |
p-Value | ||
|---|---|---|---|---|---|
| Underlying disease before the sepsis on admission | |||||
| Healthy before the admission | 9 (39.1%) | 10 (41.7%) | 56 (48.3%) | 0.065 | |
| Metabolic diseases | 8 (34.8%) | 2 (8.3%) | 13 (11.2%) | ||
| Neurologic | 1 (4.3%) | 3 (12.5%) | 16 (13.8%) | ||
| Haematology-oncology | 2 (8.7%) | 2 (8.3%) | 6 (5.2%) | ||
| Congenital heart diseases | 1 (4.3%) | 0 | 8 (6.9%) | ||
| Others | 2 (8.7%) | 7 (29.2%) | 17 (14.7%) | ||
| Sex (male) | 11 (47.8%) | 11 (45.8%) | 63 (54.3%) | 0.679 | |
| Age, years | 1.0 (2 days–17.58 years) | 7.0 (5 months–17.83 years) | 1.0 (2 days–17.50 years) | <0.001 | |
| Prognostic factors | |||||
| IMV support | 14 (60.9%) | 10 (41.7%) | 57 (49.1%) | 0.124 | |
| Inotropic drug use | 17 (73.9%) | 17 (70.8%) | 58 (50.0%) | 0.107 | |
| RBC transfusion | 22 (95.7%) | 23 (95.8%) | 83 (71.6%) | 0.003 | |
| IVIG use | 11 (47.8%) | 11 (45.8%) | 38 (32.8%) | 0.239 | |
| NIV support | 15 (65.2%) | 11 (45.8%) | 58 (50.0%) | 0.254 | |
| PRISM-III score | 24 (5–56) | 29 (6–55) | 20 (3–65) | 0.117 | |
| Duration of stay in PICU | 9.0 (48 h–52 d) | 6.0 (26 h–48 d) | 7.0 (28 h–97 d) | 0.153 | |
| Multi-organ failure | 17 (73.9%) | 12 (50.0%) | 43 (37.1%) | 0.017 | |
| Mortality | 7 (30.4%) | 7 (29.2%) | 11 (9.5%) | 0.026 | |
| Catheters’ diameters | |||||
| 6.5 and 7 Fr | 8 (34.8%) | 1 (4.2%) | - | 0.065 | |
| 8 Fr | 8 (34.8%) | 11 (45.8%) | |||
| 10 Fr | 1 (4.3%) | 2 (8.3%) | |||
| 11.5 and 12 Fr | 6 (26.1%) | 10 (41.7%) | |||
| Hemodialysis filter | |||||
| 0.2 m2 | 6 (26.1%) | 0 | - | 0.024 | |
| 0.6 m2 | 11 (47.8%) | 13 (54.2%) | |||
| 0.9 m2 or bigger | 6 (26.1%) | 8 (33.3%) | |||
| oXiris® | 0 | 3 (12.5%) | |||
| Localisation of the haemodialysis catheters | |||||
| Internal jugular | 15 (65.2%) | 18 (75.0%) | - | 0.188 | |
| Femoral | 5 (21.7%) | 6 (25.0%) | |||
| Subclavian | 3 (13.0%) | 0 | |||
| Initial settings for CRRT | |||||
| Blood flow rate (mL/min) | 56.5 (36–150) | 75.0 (40–150) | - | 0.177 | |
| Dialysate rate (mL/1.73m2/h) | 2090 (825–8355) | 2054 (1750–4550) | - | 0.843 | |
| Replacement rate (mL/kg/h) | 37.0 (29–61) | 36.0 (28–53) | - | 0.164 | |
| Duration of CRRT (hours) | 34.0 (8–189) | 45.0 (12–228) | - | 0.286 | |
| CRRT starting time | |||||
| 0–12. h | 19 (82.6%) | 22 (91.7%) | - | 0.497 | |
| 12–24. h | 3 (13.0%) | 2 (8.3%) | |||
| >24. h | 1 (4.3%) | 0 | |||
| TPE sessions | - | 3.0 (1–7) | - | - | |
| ALT (IU/L) | 0 h | 34.0 (5–534) | 48.0 (7–4388) | 20 (4–1620) | <0.001 |
| 24 h | 44.0 (7–301) | 37.0 (8–2626) | 31.0 (2–922) | <0.001 | |
| 0–24 h change | +10.5 (−234, 101) | −10.0 (−1762, 23) | +12.0 (−698, 134) | <0.001 | |
| AST (IU/L) | 0 h | 68.0 (19–1070) | 98 (19–8620) | 35.5 (8–1954) | 0.002 |
| 24 h | 61.5 (10–730) | 89.0 (20–5747) | 39.0 (1–1235) | <0.001 | |
| 0–24 h change | −8.5 (−343, 145) | −6.0 (−4523, 21) | 2.0 (−765, 234) | 0.003 | |
| HCO3 (mmol/L) | 0 h | 16.9 (9–26.5) | 13.7 (9–35.3) | 20.1 (3.5–37) | 0.113 |
| 24 h | 23.1 (7–29.5) | 23.9 (6.2–32.3) | 22.8 (8.4–29.0) | 0.351 | |
| 0–24 h change | 5.0 (−10, 13) | 6.0 (−8, 22) | 3.0 (−11, 15) | 0.773 | |
| Lactate (mmol/L) | 0 h | 4.5 (0.5–12) | 3.0 (0.5–16) | 2.25 (0.5–17) | 0.005 |
| 24 h | 2.1 (0.9–11.6) | 2.3 (1–9.7) | 2.0 (0.1–14) | 0.167 | |
| 0–24 h change | −2.5 (−9.15, 7.0) | 0.5 (−6.7, 6.3) | −0.2 (−5.4, 9.2) | 0.114 | |